UMIN ID: UMIN000054048
Registered date:04/04/2024
Progression-free, disease-free, and recurrence-free survivals as surrogate in melanoma perioperative immune checkpoint inhibitor trials.
Basic Information
| Recruitment status | Pending |
|---|---|
| Health condition(s) or Problem(s) studied | Malignant melanoma |
| Date of first enrollment | 2024/04/04 |
| Target sample size | |
| Countries of recruitment | Japan |
| Study type | Others,meta-analysis etc |
| Intervention(s) |
Outcome(s)
| Primary Outcome | The study-level outcomes of our concern will be the hazard ratios (HRs) of event-free survival (EFS, HRefs) and HR of OS (HRos). EFS includes PFS, DFS, and RFS. We will assess the Spearman's rank correlation between HRefs and HRos. |
|---|---|
| Secondary Outcome |
Key inclusion & exclusion criteria
| Age minimum | Not applicable |
|---|---|
| Age maximum | Not applicable |
| Gender | Male and Female |
| Include criteria | |
| Exclude criteria | Perioperative ICI combined with radiological treatment will be excluded. |
Related Information
| Primary Sponsor | Yokohama City University Hospital |
|---|---|
| Secondary Sponsor | |
| Source(s) of Monetary Support | Yokohama City University Hospital |
| Secondary ID(s) |
Contact
| public contact | |
| Name | Nobuyuki Horita |
| Address | 3-9, Fukuura, Kanazawa, Yokohama, Japan Japan 236-0004 |
| Telephone | 045-787-2800 |
| horitano@yokohama-cu.ac.jp | |
| Affiliation | Yokohama City University Hospital Chemotherapy Center |
| scientific contact | |
| Name | Nobuyuki Horita |
| Address | 3-9, Fukuura, Kanazawa, Yokohama, Japan Japan |
| Telephone | 045-787-2800 |
| horitano@yokohama-cu.ac.jp | |
| Affiliation | Yokohama City University Hospital Chemotherapy Center |